One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Evogene Ltd.
EVGN · NCM · Healthcare · Biotechnology
Current price
$0.37
52-week range
$0.35 - $1.33
Market cap
$5.07M
Balance sheet
Healthy
-89.39x Concerning
Net cash $7.21M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Evogene Ltd.
Evogene uses artificial intelligence to discover new seeds for farming, medicines for people, and materials for industry. Their main income comes from developing these new products and partnering with other companies to bring them to market. This approach matters because it allows Evogene to create innovative solutions across different fields without needing massive factories themselves.
How the company got here
Evogene started in 1999 as a computational biology company, meaning it uses computer power to understand biological processes. Its journey has been marked by a focus on leveraging artificial intelligence (AI) to speed up the discovery of new products in various fields. Over the years, the company has evolved, shifting its focus and structuring its operations to better commercialize its AI-driven discoveries across different industries. This strategic evolution has led to its current organization, aiming to bring innovative solutions to market faster than traditional methods.
What it actually does
Evogene uses advanced computer algorithms and artificial intelligence to discover and develop new products, primarily in the areas of agriculture and human health. Think of it like a super-smart digital lab that can sift through vast amounts of biological data to find promising new ingredients or treatments. This AI-powered approach helps them identify potential solutions for crops, medicines, and industrial materials much more efficiently than traditional research methods. Their goal is to bring these innovative products to market, improving yields for farmers or offering new therapeutic options for patients.
Agriculture
In its Agriculture segment, Evogene focuses on using its computational biology platform to develop new solutions for farming. This includes creating innovative seed traits that can help crops grow better, resist diseases, or withstand challenging environmental conditions. They also work on developing new 'ag-chemicals,' which are substances used in farming to protect crops or improve growth. The aim here is to help farmers increase their harvests and reduce losses, making food production more efficient and sustainable. This segment represents a significant part of Evogene's business, addressing critical needs in global food supply.
Human Health
The Human Health segment is where Evogene applies its AI capabilities to discover and develop new medicines. They utilize a powerful AI engine called ChemPass to design novel small molecules, which are the building blocks for many drugs. These efforts are directed towards creating treatments for various diseases, including hyper-inflammatory conditions and cardiovascular diseases. By identifying promising drug candidates, Evogene aims to accelerate the drug development process, potentially bringing new and effective therapies to patients faster than traditional pharmaceutical research. This segment is a key growth area for the company, focusing on unmet medical needs.
Industrial Applications
Evogene's Industrial Applications segment leverages its computational biology expertise for non-medical, non-agricultural uses. A primary focus here is on the development and commercialization of castor bean seeds, which have various industrial applications, such as in the production of biofuels and bioplastics. This segment demonstrates the versatility of Evogene's AI platform, showing how it can be applied to create sustainable solutions for industries beyond healthcare and agriculture. While perhaps a smaller slice of the overall business compared to agriculture or human health, it represents an avenue for diversification and innovation.
What management is betting on now
Management is currently focused on advancing its pipeline of AI-discovered products across its key segments, particularly in agriculture and human health. They are prioritizing the development of novel seed traits and ag-chemicals to enhance crop yields and resilience, as well as accelerating the discovery of new drug candidates for challenging diseases. A key strategic priority is to effectively commercialize these innovations, either through partnerships or direct product launches. By continuing to invest in and refine its computational biology platform, Evogene aims to maintain its edge in AI-driven product development and capture significant market opportunities.
Price history
How the share price has moved
—
Loading price history…
Is it cheap or expensive?
Fair value — vs current price $0.37
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $7.2M - more cash than debt. Interest coverage -89.4x.
Net debt
$-7.21M
Interest coverage
-89.39x
Evogene Ltd.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 2 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
EVGN
BASELINE
Evogene Ltd.
Total debt $2.10M Interest coverage -89.39x This is the baseline the peer rows are being compared against.
Total debt $0.00 Interest coverage -499.75x Neither company has much profit cushion over interest right now.
Total debt $1.75M Interest coverage -7.85x Neither company has much profit cushion over interest right now.
What you should know
The case for and against EVGN
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -182.7% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.62x
P/B
-1.53x
P/S
3.06x
EV/EBITDA
-0.49x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
-67.6%
Operating margin
-606.6%
Net margin
0.0%
ROE
-182.7%
ROA
-37.5%
Health
Liquidity and balance-sheet strength
Debt / equity
0.36x
Current ratio
3.57x
Quick ratio
3.23x
Total debt
$2.10M
Total cash
$9.32M
Growth
How the business has been compounding
Revenue TTM
$1.66M
Revenue 5Y CAGR
32.0%
EPS TTM
-1.55
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-13.50M
Free CF TTM
$-13.64M
FCF margin
-823.0%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—